Search This Blog

Wednesday, December 11, 2024

Wall Street Reacts To CPI Report, Even As Markets Price In Certainty Of Dec Rate Cut

 Today's CPI report - the final important economic report of 2024 - came on the screws with every Inflationary metric coming in as expected (if somewhat hotter when looked at a bit closer). Still, the market was relieved that the print did not beat estimates (as some whispers hinted), and for many this was enough to assure that the Fed cuts rates by 25bps next week before potentially pausing in January. Many... but not all.

As the following kneejerk reaction snapshots from a selection of Wall Street analysts, strategists and economists suggests, even today's print wasn't enough to assure everyone that a 25bps cut is a done deal, even if market implied odds are now up to 97.9%

Below we excerpt several key post-CPI soundbites:

Neil Birrell, Premier Miton Investors

"This report will give the Fed confidence. Investors will also take heart, as the lack of a surprise, good or bad, allows for more certainty in decision making in the short term.”

David Russell, head of market strategy at TradeStation:

“No news is good news. Inflation has stopped falling, but it isn’t enough of a problem to derail this bull market. Inflation and the Fed are becoming less of a catalyst. Attention could now shift to the incoming administration’s tariff policy.”

Brian Coulton, chief economist at Fitch Ratings:

“The decline in core goods prices – which was a big part of the overall disinflation story this year – looks to be over, with core goods prices rising 0.3% month-on-month as car prices jumped. Services inflation is coming down but only very slowly – as rental inflation proves stubborn – and, at 4.6%, remains far higher than pre-pandemic rates.”

Anna Wong, head of Bloomberg Economics:

“November’s sturdy core CPI reading will inflame worries among the FOMC minority that disinflation has stalled. True, housing-rent inflation finally stepped down — as market rents have long suggested — but goods prices have lost disinflation momentum. The current monthly inflation pace is consistent with an annual inflation rate above 3%, not with the Fed’s 2% target. The November CPI report likely implies that the Fed’s preferred price gauge, the core PCE deflator, may edge up to 2.9% for the last two months of 2024. We still think the FOMC is slightly more likely than not to cut rates again in at December’s meeting, but we don’t think it’s a done deal.”

Nick Timiraos, Fed Mouthpiece, WSJ

"Falling prices (deflation) of core goods over the last 18 months helped deliver a decent chunk of the disinflation we've seen. That has now ended, with higher car prices pushing up core goods 0.3% on the month (after +0.05% in October and +0.17% in September)."

Lael Brainard, Biden's National Economic Adviser:

“For four months in a row now, inflation has been close to the level right before the pandemic. While price increases have been hard for working families, household incomes are up almost $4,000 more than prices during this Administration. We will continue to fight to lower costs for American families.”

Jeffrey Roach of LPL Financial:

“Roughly a third of the inflation metric is ‘Owners’ Equivalent Rent,’ an imputed value and not a realized expense for homeowners. Wages are growing faster than inflation, putting consumers on good footing as they enter the new year. The Fed will likely stay on course to slowly and methodically cut rates as the more sticky components of inflation are stabilizing.”

Ira Jersey, Bloomberg Rates strategist:

“Inflation is all services these days, which of course is in large part housing-related, but the point here is that goods inflation right now is very tepid. Tariffs risk upsetting this for a period of time, but it’s unclear how broader inflation will react. We suspect the first order is for firms to pass along costs as much as they can... The rally in the front end from the release of the CPI report reflects some relief by the market that inflation didn’t rebound. Yet we note the drivers of inflation haven’t changed: With services inflation continuing to run at 4.5% year over year, it’s unlikely core inflation will reach the Fed’s target anytime soon.”

Ali Jaffery, CIBC Capital Markets:

"Underneath the hood, the picture was not so bad for  inflation. If you strip out used cars, then core good prices rose just 0.1% on the month, he says. And services inflation slowed alongside shelter. Even so, there are doubts about the magnitude of 2025 rate cuts. The threat of a pause and a stretched out easing cycle is growing if growth doesn’t slow or aggregate price pressures don’t cool a bit more."

John Brady, RJ O’Brien

“Jan is a skip and they will cut in December, because they have to, as their initial move and dot-plot outlook in September locked them in."

Richard Flynn, Charles Schwab UK

“Several Fed speakers have recently indicated that they are unsatisfied by the rate of improvement in inflation and the regression in November fails to provide reassurance on that front. This may lead policymakers to err on the side of caution, opting for a pause in cutting interest rates to avoid bolstering pressure on prices.”

Michael Brown, Pepperstone

"The figures shouldn’t deter the FOMC from a quarter-point cut next Wednesday. However, risks around the monetary policy outlook are set to become increasingly two-sided in the first quarter of next year. Chiefly, policymakers will be concerned about the potential upside inflation risks stemming from incoming President Trump’s tariff plans, as well as the broader reflationary fiscal stance, whereby strong demand could further fuel price pressures.”

Source: Bloomberg

https://www.zerohedge.com/markets/wall-street-reacts-cpi-report-even-markets-price-certainty-dec-rate-cut

Loonie Strengthens As BoC Slashes Rates 50bps Again, Blames De-Growth On Trump & Immigration

 The Bank of Canada just slashed rates by 50bps (to 3.25%) - as expected - and the second 50bps cut in a row as the central bank claimed growth looks weaker than expected... but they were careful to tamp down any exuberance over future cuts.

The bank said it cut by 50 basis points to “support growth and keep inflation close to the middle of the 1-3% target range,” citing inflation near 2%, excess supply, and softer-than-expected growth.

The decision was expected by markets and most economists in a Bloomberg survey.

Slightly hawkish shift in language...

  • The central bank said it will be “evaluating the need for further reductions in the policy rate one decision at a time.”

  • By comparison, October’s policy statement said that “if the economy evolves broadly in line with our latest forecast, we expect to reduce the policy rate further.”

Who's to blame for the slower growth? Trump and Immigration...

Donald Trump’s threat to impose 25% tariffs on Canadian exports to the US has “increased uncertainty and clouded the economic outlook,” the bank said.

“No one knows how this will play out in the months ahead — whether tariffs will be imposed, whether exemptions get agreed, or whether retaliatory measures will be put in place,” Governor Tiff Macklem said.

Lower immigration targets mean GDP growth next year will likely be weaker than forecast in October, the bank said.

Inflation impacts will likely be muted as lower immigration reduces both demand and supply.

Additionally, the bank mentioned other government policies and said it won’t react to temporary effects, placing more emphasis on underlying trends in inflation. A temporary sales tax holiday will lower inflation to around 1.5% in January, but the effect should be unwound after mid-February.

BoC's Macklem says:

  • "Monetary policy no longer needs to be clearly in restrictive territory"; previous "cuts will be working their way through the economy"

  • "Economy remains in excess supply and the growth outlook now appears softer than we projected in October".

  • "We will be looking at measures of core inflation to help us assess the trend in CPI inflation."

  • "We expect the GST [tax] holiday to temporarily lower inflation to around VA% in January, but that effect will be unwound after the GST break ends in mid- February."

  • "The economic outlook is clouded by the possibility of new tariffs on Canadian exports to the United States."

  • "Our policy focus now is to keep inflation dose to target."

  • "We want to see growth pick up to absorb the unused capacity in the economy and keep inflation dose to 2%."

  • "We thought elevated shelter price inflation would continue to ease, and it has."

The Loonie strengthened on the BoC's move

Source: Bloomberg

Canadian stocks advanced, while bonds pared gains after BoC rate cut.

Mangione's Lawyer Says He's Not Seen Evidence Showing Client Is Guilty

 by Zachary Stieber via The Epoch Times,

The attorney hired to represent the man accused of killing UnitedHealthcare’s CEO said that he’s seen no evidence showing his client is guilty.

“I haven’t seen any evidence that says that he’s the shooter,” Thomas Dickey told reporters in Pennsylvania on Dec. 10, after a hearing in which his client Luigi Mangione was denied bail.

Law enforcement officials say Mangione is the individual who approached UnitedHealthcare CEO Brian Thompson on a New York City sidewalk earlier this month and fatally shot him in the back.

Dickey said Mangione plans to plead not guilty and urged people to remember that in the American justice system, defendants are innocent until proven guilty.

“The burden is always on the government, thank God, and that’s their burden, and they’re going to have to produce some evidence, and we’re anxious to see it,” said the lawyer, who announced during the hearing that he was fighting government attempts to extradite Mangione to face charges.

The challenge prolongs what can be a relatively quick process when defendants waive their right to fight extradition. The U.S. Constitution’s Extradition Clause provides that, upon the demand of the governor of the state from which a fugitive fled, the fugitive be delivered to that state.

New York Gov. Kathy Hochul said in a statement that she was grateful for law enforcement arresting Mangione. She said that she would be signing a governor’s warrant “to ensure this individual is tried and held accountable.”

The judge in the hearing gave Mangione 14 days to file a petition formally challenging the extradition. The judge gave prosecutors 30 days to obtain the New York governor’s warrant.

“We’re going to do what’s necessary to get the governor’s warrant and we’re working with the New York City Police Department and the Manhattan DA’s office and we’re going to get the defendant out there so they can prosecute him on their charges,” Blair County District Attorney Pete Weeks told reporters in a briefing after the hearing.

“So, waiving accelerates that process. Contesting it just provides more hoops for law enforcement and prosecutors to jump through but we’re happy to do that.”

Mangione was arrested at a McDonald’s in Altoona after a customer alerted police. Officers found Mangione with multiple fake IDs, a firearm, and a silencer, according to police.

Mangione suffered a back injury, according to friends and others, and underwent back surgery. Joseph Kenney, an NYPD official, said on Fox News that some of the writings that police allegedly found on the defendant were “discussing the difficulty of sustaining that injury.” Police were still looking into a possible nexus with insurance.

Dickey, Mangione’s lawyer, declined to talk about his client’s injury.

Mangione on his way into the hearing shouted, “It’s completely out of touch and an insult to the American people and their lived experience.”

“He seems outspoken,” Dickey said. As a defendant, it’s natural to experience a range of emotions, the lawyer said. Dickey said he wants to do all of the talking moving forward. “Hopefully there won’t be any more of that,” he said, regarding the shouting.

Dickey has met with his client. When asked by reporters about his first impressions of his client, Dickey said, “I wasn’t looking for impressions. What I was trying to do was form a bond with my client, I want him to trust me, and I want him to be confident that I’m here for him, and I feel that I’m very pleased with how that went.”

Luigi Mangione leaves the Blair County Courthouse in Hollidaysburg, Pa., on Dec. 10, 2024. Jeff Swensen/Getty Images

The lawyer said he was hired. He would not say who hired him.

Mangione grew up in Maryland, and his family owns a country club there. A cousin, Nino Mangione, is a member of the Maryland House of Delegates. Relatives declined requests for interviews.

“Unfortunately, we cannot comment on news reports regarding Luigi Mangione. We only know what we have read in the media,“ the family said in a previous statement. ”Our family is shocked and devastated by Luigi’s arrest. We offer our prayers to the family of Brian Thompson, and we ask people to pray for all involved. We are devastated by this news.”

https://www.zerohedge.com/political/luigi-mangiones-lawyer-says-hes-not-seen-evidence-showing-client-guilty

Anaptys Phase 2b Misses Primary, Secondary Endpoints in Atopic Dermatitis

 

  • ANB032 was well tolerated across all doses with no safety signals observed
  • AD trial and all further investment in ANB032 will be discontinued
  • Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonist
  • Funded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101
  • Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-end 2027, excluding potential GSK milestones and royalties

Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment

Q32 Bio (QTTB) delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse amid a series of downgrades and price-target cuts.

The company tested its drug, bempikibart, in patients with atopic dermatitis and alopecia areata. In the eczema study, an outsized placebo response torpedoed the results. And bempikibart looked less effective than already approved drugs in alopecia treatment, said Piper Sandler analyst Christopher Raymond, who described the results as "messy."

Now, Q32 Bio is discontinuing its efforts in eczema treatment and running another study in alopecia patients.

Raymond slashed his price target on the biotech stock to 20 from 85. Shares has an even worse fate at Leerink Partners where analyst Thomas Smith lowered his price target to 9 from 68. He also downgraded the stock to a market perform rating from outperform.

Q32 Bio stock crashed more than 67% to 8.02 in morning trades on the stock market today. Shares hit a record low, underscoring their previous low point at 8.24 in November 2023.

https://www.investors.com/news/technology/biotech-stock-q32-bio-stock-eczema-alopecia-treatment/

Cellectar Biosciences Provides Strategic Update

 Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity

Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies

https://www.globenewswire.com/news-release/2024/12/10/2994986/29076/en/Cellectar-Biosciences-Provides-Strategic-Update-on-Clinical-Development-Pipeline-Programs-and-Corporate-Restructuring.html

Candel achieves primary endpoint in prostate cancer Phase 3

 n Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.

The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone.

CAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells by exposing them to tumor antigens in the context of an activated tumor microenvironment.

Key topline results include:

  • Statistically significant improvement in disease-free survival (DFS) for CAN-2409 plus radiation therapy (n=496) vs. radiation therapy alone (n=249) (p=0.0155; HR 0.7) in the intent-to-treat population.

  • At 54 months, the CAN-2409 treatment arm observed a 14.5% relative improvement in DFS compared to the placebo control arm.

  • DFS improvement was observed in patients receiving short-term ADT and those not receiving ADT.

  • In an analysis that focused on prostate-specific outcomes, CAN-2409 showed a highly significant effect on prostate cancer-free survival.

  • A significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir (<0.2 ng/ml) was observed in the treatment arm compared to the placebo control arm (67.1% vs. 58.6%, respectively; p<0.0164).

  • CAN-2409 induced 80.4% pathological complete responses (pCRs) in the 2-year post-treatment biopsies compared to 63.6% observed in the control arm (p=0.0015).

  • The median follow-up time for the recruited population was 50.3 months.

  • The safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. The most common CAN-2409-related adverse events were flu-like symptoms, fever and chills, which were generally mild to moderate in severity and self-limited.

    The company also reported that the phase 2 clinical trial of monotherapy CAN-2409 in 190 patients with low-to-intermediate risk localized prostate cancer undergoing active surveillance.

    The trial showed numerical improvement in time to radical treatment and the percentage of patients achieving negative (prostate cancer-free) biopsies at 1-year post-treatment. However, these differences did not reach statistical significance.